肝硬化中的钠-葡萄糖协同转运蛋白2抑制剂：一条有前景但存在潜在风险的治疗途径。 - Suppr

Suppr

超能文献

SGLT2 Inhibitors in Cirrhosis: A Promising Therapeutic Avenue with Potential Risks.

作者信息

Loyola-Vélez Alejandro J, John Binu V

机构信息

Florida International University and Miami VA Medical System, Miami, FL, USA.

Division of Gastroenterology and Hepatology, Miami VA Medical System, Miami, USA.

出版信息

Dig Dis Sci. 2025 Feb;70(2):456-458. doi: 10.1007/s10620-024-08703-3. Epub 2024 Nov 24.

DOI:10.1007/s10620-024-08703-3

PMID:39581899

Abstract

摘要

相似文献

SGLT2 Inhibitors in Cirrhosis: A Promising Therapeutic Avenue with Potential Risks.

Dig Dis Sci. 2025 Feb;70(2):456-458. doi: 10.1007/s10620-024-08703-3. Epub 2024 Nov 24.

The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review.

J Clin Med. 2023 Mar 14;12(6):2253. doi: 10.3390/jcm12062253.

SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension.

J Diabetes. 2021 Mar;13(3):265-269. doi: 10.1111/1753-0407.13136. Epub 2020 Dec 6.

Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes.

Healthcare (Basel). 2024 Mar 29;12(7):753. doi: 10.3390/healthcare12070753.

Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.

BMC Gastroenterol. 2023 Dec 19;23(1):450. doi: 10.1186/s12876-023-03085-8.

Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use.

Liver Int. 2024 Apr;44(4):884-893. doi: 10.1111/liv.15851. Epub 2024 Jan 31.

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Curr Diab Rep. 2022 Jul;22(7):317-332. doi: 10.1007/s11892-022-01471-2. Epub 2022 May 28.

Risks Associated with SGLT2 Inhibitors: An Overview.

Curr Drug Saf. 2018;13(2):84-91. doi: 10.2174/1574886313666180226103408.

SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.

J Pharm Pharmacol. 2013 Mar;65(3):317-27. doi: 10.1111/j.2042-7158.2012.01574.x. Epub 2012 Aug 9.

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

Medicina (Kaunas). 2023 Apr 10;59(4):742. doi: 10.3390/medicina59040742.

本文引用的文献

Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.

Clin Gastroenterol Hepatol. 2024 Apr;22(4):778-788.e7. doi: 10.1016/j.cgh.2023.11.020. Epub 2023 Dec 5.

HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis.

Hepatol Commun. 2023 Dec 7;7(12). doi: 10.1097/HC9.0000000000000344. eCollection 2023 Dec 1.

Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites.

Hepatology. 2024 Apr 1;79(4):844-856. doi: 10.1097/HEP.0000000000000577. Epub 2023 Aug 25.

Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.

Diabetes Obes Metab. 2021 Oct;23(10):2402-2408. doi: 10.1111/dom.14488. Epub 2021 Jul 28.

Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.

Hepatology. 2021 Aug;74(2):1014-1048. doi: 10.1002/hep.31884.

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.

Circulation. 2020 Jan 14;141(2):90-99. doi: 10.1161/CIRCULATIONAHA.119.044138. Epub 2019 Nov 17.

The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure.

JAMA Cardiol. 2017 Sep 1;2(9):939-940. doi: 10.1001/jamacardio.2017.1891.

Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis.

J Hepatol. 2015 Nov;63(5):1272-84. doi: 10.1016/j.jhep.2015.07.004. Epub 2015 Jul 17.

Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

World J Gastroenterol. 2009 Jan 21;15(3):280-8. doi: 10.3748/wjg.15.280.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验